Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease

BACKGROUND: Interleukin-1 inhibition has revealed to be a successful treatment approach for patients with adult-onset Still's disease (AOSD). However, real-life experience is focused on the use of anakinra, while data about canakinumab (CAN) are mainly based on case reports and small case serie...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mediators Inflamm
Autori principali: Vitale, Antonio, Berlengiero, Virginia, Sota, Jurgen, Ciarcia, Luisa, Ricco, Nicola, Barneschi, Sara, Mourabi, Mariam, Lopalco, Giuseppe, Marzo, Chiara, Bellisai, Francesca, Iannone, Florenzo, Frediani, Bruno, Cantarini, Luca
Natura: Artigo
Lingua:Inglês
Pubblicazione: Hindawi 2020
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7584965/
https://ncbi.nlm.nih.gov/pubmed/33122969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/8054961
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi